Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47% over the period 2014-2019, finds new report

Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.

Publisher's analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.

According to the report, one of the main drivers of this market is the increase in the aging population. The elderly in both developing and developed countries have an increased risk of developing congestive heart failure and other ailments.

This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.

The Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

• Americas
• APAC
• EMEA

Key Vendors

• AstraZeneca
• Bristol-Myers Squibb
• GSK
• Merck & Co.
• Mylan
• Novartis
• Pfizer
• Sanofi
• Valeant Pharmaceuticals

Other Prominent Vendors

• Bayer
• Bioheart
• Boehringer Inhelheim
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries

Market Driver

• Increase in Aging Population
• For a full, detailed list, view our report

Market Challenge

• Weak Pipeline
• For a full, detailed list, view our report

Market Trend

• Increase in Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 120 pages, “Global Congestive Heart Failure Drugs Market 2015-2019” report covering the Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Market Landscape, Market Segmentation by Therapeutic Class,  Late Stage Pipeline Molecules, Geographical Segmentation,  Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their Impact, Vendor Landscape, Key Vendor Analysis. The report covered companies are - AstraZeneca, Bristol-Myers Squibb, GSK, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Valeant Pharmaceuticals, Bayer, Bioheart , Boehringer Inhelheim , Takeda Pharmaceutical , Teva Pharmaceutical Industries

For further information on this report, please visit- http://mrr.cm/4id

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare